-
Underground insulin exchanges emerge as workers lose jobs, insurance co-pays fall short
DENVER — D.j. Mattern had her Type 1 diabetes under control until COVID-19’s economic upheaval cost her husband his hotel maintenance job and their health coverage. The 42-year-old Denver woman suddenly faced insulin’s exorbitant list price — anywhere from $125 to $450 per vial — just as their household income…
-
Type 1 diabetes could begin in the womb, new research suggests
Type 1 diabetes can develop in babies under six months old, and the immune attack behind the condition may begin before they’re born, a new study co-funded by Diabetes UK has suggested for the first time. Until recently, it was thought that children under six months could only develop neonatal…
-
Treatment Reverses Type 1 Diabetes. Will It Last?
After starting a drug that’s officially approved to treat a type of blood cancer, a young man with type 1 diabetes was able to stop using insulin. He’s been off insulin since August 2018 — more than two years. Dr. Lisa Forbes — his doctor and co-author of a letter…
-
Full funding announced for continuous Type 1 diabetes management systems
The Yukon government will now fund continuous glucose monitoring systems for Type 1 diabetics after local advocates began asking for donations from businesses to make up for a lack of government coverage. “We recognize the challenges Yukoners and families who live with Type 1 diabetes face on a daily basis…
-
Has the Pandemic Changed Type 1 Diabetes Care for Good?
MONDAY, Oct. 5, 2020 (HealthDay News) — When the COVID-19 pandemic began, many doctors started providing care via telemedicine. Now, a new survey of people with type 1 diabetes suggests many like remote care and hope it continues in the future. Among the survey respondents who had a telemedicine visit…
-
Dexcom Signs Multi-Year Collaboration Agreement with the University of Virginia…
SAN DIEGO–(BUSINESS WIRE)–DexCom, Inc. (NASDAQ:DXCM) today announced it has signed a five-year collaboration agreement with the University of Virginia to advance its research and development efforts on continuous glucose monitoring-based solutions. The research partnership will center on advancing Dexcom’s automated insulin delivery technology and exploring the use of continuous glucose…
-
Britons With Type 1 Diabetes Die Nearly 8 Years Earlier
Britons With Type 1 Diabetes Die Nearly 8 Years Earlier — But keeping HbA1c in check can mitigate this early mortality by Kristen Monaco, Staff Writer, MedPage Today September 23, 2020 The average British adult with type 1 diabetes loses about eight life-years compared with nondiabetic age peers, according to…
-
Bioprinted therapeutic offers novel solution for treating Type 1 Diabetes
VANCOUVER, BC, Sept. 22, 2020 /CNW/ – Type 1 Diabetes (T1D), once known as insulin dependent diabetes, is a chronic condition that causes pancreatic cells to produce little or no insulin. Insulin plays an important role in regulating blood sugar, or glucose, so T1D patients cannot naturally regulate their blood…
-
Penn study proves promising for type 1 diabetes cure
After a promising study by Penn researchers, a cure for type 1 diabetes appears to be closer to reality. A research team led by Penn scientists successfully transplanted insulin-producing cells into multiple animal models, PhillyVoice reported. In type 1 diabetes, beta cells in clusters called islets cannot regulate blood sugar…
-
Rethinking Type 1 diabetes with a radically new immunotherapy approach
Jean Van Rampelbergh PhD, VP Clinical & Regulatory at Imcyse SA, introduces Imotopes™, the innovative new immunotherapy approach causing scientists to rethink Type 1 diabetes and its treatment Severe and chronic autoimmune diseases are some of the most difficult and complex immune system-related diseases to treat. Normally, the immune system…
